Table 3.

Pharmacokinetic Parameters of Cyp2d1 and Cyp2c11 Enzymes on Probe Substrates Dextromethorphan and Tolbutamide in Group A, Group B and Group C Rats

Parameters	Dextromethorphan			Tolbutamide
	Group A	Group B	Group C	Group A	Group B	Group C
AUC(0-t) (μg/h*L)	528.54 ± 203.95*	283.95 ± 53.36*	98.74 ± 38.58	69,246.07 ± 17,188.27*	53,448.80 ± 11,999.02*	31,763.24 ± 2849.57
AUC(0-∞) (μg/h*L)	556.74 ± 207.73*	288.27 ± 54.72*	100.40 ± 39.54	125,226.57 ± 56,483.83*	87,092.94 ± 23,760.89*	37,274.32 ± 2968.84
MRT(0-t) (h)	3.10 ± 0.29*	2.83 ± 0.41	2.57 ± 0.46	10.52 ± 1.01*	10.49 ± 0.44*	8.43 ± 0.34
MRT(0-∞) (h)	3.84 ± 0.58*	3.01 ± 0.42	2.77 ± 0.53	21.47 ± 4.44*	24.81 ± 2.58*	12.79 ± 3.60
t1/2z (h)	2.98 ± 0.67*	1.91 ± 0.41	2.02 ± 0.36	14.66 ± 3.1*	16.65 ± 1.64*	8.40 ± 3.46
Tmax (h)	0.54 ± 0.25	0.46 ± 0.10	0.54 ± 0.25	8.00 ± 3.35*	6.33 ± 3.39	3.33 ± 0.82
Vz/F (L/kg)	86.18 ± 38.25*	98.64 ± 28.33*	325.53 ± 117.90	0.24 ± 0.08	0.29 ± 0.07	0.32 ± 0.12
CLz/F(L/h/kg/)	19.78 ± 6.04*	35.85 ± 7.36*	111.28 ± 36.30	0.01 ± 0.005*	0.012 ± 0.004*	0.027 ± 0.003
Cmax (μg/L)	186.83 ± 103.34*	99.85 ± 33.92*	45.14 ± 18.57	4056.45 ± 1169.27	3239.97 ± 879.06	2972.225 ± 340.64

Notes: N = 6, *P <0.05, there is statistical significance between Group A, Group B and Group C; Group A, multiple-dose avitinib group; Group B, single-dose avitinib group; Group C, control group.

Abbreviations: AUC, area under the curve; MRT, mean residence time; t_1/2z, the apparent elimination half-life; T_max, maximum plasma concentration; Vz/F, apparent volume of distribution; CLz/F, apparent total clearance; C_max, the maximum plasma drug concentration.